Oramed Pharmaceuticals Announces Maiden Year Progress Report



    JERUSALEM, March 13 /CNW/ -- Oramed Pharmaceuticals Inc. (OTC Bulletin
Board: ORMP, FTSE: OJU), an Israel based company, is proud to announce its 1
year anniversary and accomplishments.
    CEO Nadav Kidron states, "Over the past year we have hit many great
milestones for our supporting shareholders including surpassing the
International Review Board and Ministry of Health approvals to further our
initial flagship product, oral insulin, toward human clinical trials.  In
addition, we were able to gain the support of Swiss Caps, one of the largest
manufacturers of soft gel capsules in the world, to accept us as a client and
to support our company with their validation of our technology in producing
our capsules for a direct share exchange in lieu of a cash payment.
    Between the end of 2006 and the beginning of 2007, we approached and
succeeded in building an internationally known scientific board, containing
very strong contacts within the NIH (National Institution of Health), ADA
(American Diabetes Association), Hadassah Research Hospital, and many other
well-known institutions both professional and educational.  Their expertise
expands within Endocrinology, Immunology, Diabetes and Medicinal practices
globally, with strengths in greater Europe, South Africa, and North America
    This has enabled us to further our horizons and focus on innovations in
medicinal research.  Within our first year, Oramed is in the process of
registering I.P. over another method of Insulin delivery. In addition, we have
begun pre clinical testing on an oral replacement for the highly demanded flu
vaccine, with over a billion doses disseminated annually, as reported by the
CDC.
    We are pragmatically enhancing our pipeline to incorporate new
technologies to help take the pinch out of life for many suffering patients
with debilitating diseases as well as enable a larger percentage of the
population to take necessary vaccinations and maintain a healthier lifestyle.
    We look forward to another strong year of developments and expansion as
we move forward with great hope.
    For more information on Oramed Pharmaceuticals please visit our website:
www.oramedpharma.com

    
    Legal Notice Regarding Forward-Looking Statements
    
    This news release contains statements, which may constitute  "forward-
looking statements". Those statements include statements regarding the intent,
belief or current expectations of Oramed Pharmaceutical Inc., and members of
our management as well as the assumptions on which such statements are based.
Forward-looking statements in this release include: that Oramed is in the
process of registering I.P. over another method of Insulin delivery; that we
have begun pre clinical testing on an oral replacement for the highly demanded
flu vaccine, with over a billion doses disseminated annually; that we are
enhancing our pipeline to incorporate new technologies to help take the pinch
out of life for many suffering patients with debilitating diseases as well as
enable a larger percentage of the population to take necessary vaccinations
and maintain a healthier lifestyle; and that we hope to have another strong
year of developments and expansion.. Factors which may significantly change or
prevent our forward looking statements from fruition include that we may be
unsuccessful in developing any products; we may be unable to raise funds and
resources to pursue research and development; our patent applications may not
be accepted by the patent office; we may be unable to successfully defend our
patents from infringement by third parties, there is a risk that our patents
may be subsequently shown to be invalid or infringe the patents of others, our
products may never gain FDA or other regulatory body approval for human
consumption and we may be unable to successfully commercialize our future
products. Readers should refer to our most recent period reports filed on
Edgar.

    
    Investor Relations Contact:
     Oramed Pharmaceuticals, Inc.
     Vinisha Agnihotri
     (646) 467-2252
     info@oramedpharma.com
     www.oramedpharma.com

    




For further information:

For further information: Investor Relations Contact - Vinisha Agnihotri,
 Oramed Pharmaceuticals, Inc., +1-646-467-2252, info@oramedpharma.com Web
Site: http://www.oramedpharma.com

Organization Profile

ORAMED PHARMACEUTICAL, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890